# Volume 19 Index

	Month
Pages	(Issue No.)
1-58	January (1)
59-116	February (2)
117-174	March (3)
175-232	April (4)
233-298	May (5)
299-360	June (6)
361-418	July (7)
419-476	August (8)
477-534	September (9)
535-592	October (10)
593-650	November (11)
651-716	December (12)

#### **Author Index**

Abrass IB. Drugs: A Special Problem in the Treatment of the Elderly, 638 Adkins PC. See Geelhoed GW

Barnard J. See Greene JW

Dunham WK. The ABCs of Exercise Physiology: A Foundation for Preventive Health Care (CME), 554

Ebersold MJ, Marsh WR, Onofrio BM. Chemonucleolysis in the Treatment of Lumbar Disc Disease (CME), 337

Eden AN. Treatment of Childhood Obesity, 315 Ettinger LD. See Solomon DA

Finlayson RE. Depression That Does Not Respond to Drugs (CME), 504

Fisher JV. The Family Physician's Role in Managing Alcohol and Drug Abuse: A Response to Stephens's Decalogue, 129

Flaker Ġ, Munuswamy K. Evaluation of Syncope With Intracardiac Electrophysiologic Testing (CME), 453

Geelhoed GW. Multiple System Failure in the Critically Injured Patient (CME), 75

Geelhoed GW. The Use and Abuse of Systemic Antibiotics in Surgical Patients (CME), 391

Geelhoed GW, Zimmerman JE, Adkins PC. Uses and Abuses of Albumin: Guidelines for Colloid Therapy, 585 Goldenberg RL, Nelson KG, Humphrey JL, Wayne JB. Mortality and Morbidity in the Perinatal Period, 435

Grau RG. Management of Raynaud's Phenomenon (CME), 200

Grauer K. Differentiating Between Aberrantly Conducted Beats and Ventricular Ectopy (CME), 85

Greene JW, Barnard J. Recurrent Abdominal Pain in Childhood and Adolescence (CME), 256

Holten KB, John PG. Sudden Death in Salicylate Overdose, 191 Humphrey JL. See Goldenberg RL

Jablecki CK. Amyotrophic Lateral Sclerosis (CME), 138 James EJP. See Monzon CM John PG. See Holten KB

Kansal PC. Regulation of Diabetes Mellitus With the Biostator, 490 Katzenstein DA. The Sexual

Transmission of Viral Infections (CME), 18

Kendall AR. Benign Prostatic Hyperplasia: Medical Evaluation, Treatment, and Operative Indications (CME), 680

Kenny JD, Ritter DA. The Intrauterine Growth-Retarded Infant (CME), 689

Laws HL. The Current Role of Surgery in the Management of Duodenal Ulcer (CME), 383

Marsh WR. See Ebersold MJ Mohammad AM. See Monzon CM Monzon CM, Mohammad AM, James EJP. Evaluation of Hemolysis in the Neonate (CME), 211 Munuswamy K. See Flaker G

Nelson KG. See Goldenberg RL

Onofrio BM. See Ebersold MJ Orr JW Jr. The Laser in Gynecology (CME), 567

Panush RS. All Aches Are Not Arthritis: Nonarticular Rheumatism, 375

Pepine CJ. Clinical Use of Calcium-Channel Blockers in Cardiovascular Disease (CME), 13

Petty TL. Chronic Obstructive

Pulmonary Disease Management (CME), 510

Quan MA. See Rodney WM Quinlan RW. A Structured Approach to Antenatal Ultrasound Examinations (CME), 611

Ritter DA. See Kenny JD Rodney WM, Quan MA, Sakiyama R, Vincent C. The Low T<sub>5</sub> (Euthyroid Sick) Syndrome in the Elderly: A Practical Diagnostic Approach (CME), 463

Sakiyama R. See Rodney WM Siegel RL. T and B Cell Abnormalities in Immunologic Diseases (CME), 264

Solomon DA, Ettinger LD. Prophylaxis of Pulmonary Emboli: A Critical Assessment (CME), 330

Stead EA Jr. The Cholesterol Controversy Continues, 249 Susman JL. Problems in Thyroid Endocrinology (CME), 145

Talley JH. A Useful Patient Handout in the Management of Depression, 280

Vincent C. See Rodney WM

Watts C. The Management of Ruptured Intervertebral Disc Disease by Chemonucleolysis, 667 Wayne JB. See Goldenberg RL

Zimmerman JE. See Geelhoed GW

## **Editorial Index**

American Medicine Transformed, 6 Which Physicians Will Care for the Nation's Children? 68 A Decalogue for the Management

A Decalogue for the Management of Alcohol and Drug Abuse, 125 Salicylate Poisoning, 184 The Medical Supermarket:

Futuristic of Decadent? 243 Home Deliveries—Why? 315 Testing, Antiknowledge, and Negat-

ing the Negative, 371
American Medicine and the
Enchanted Machine, 428
The Man With a Renal Cyst. 48

# Volume 19 Index

	Month
Pages	(Issue No.)
1-58	January (1)
59-116	February (2)
117-174	March (3)
175-232	April (4)
233-298	May (5)
299-360	June (6)
361-418	July (7)
419-476	August (8)
477-534	September (9)
535-592	October (10)
593-650	November (11)
651-716	December (12)

#### **Author Index**

Abrass IB. Drugs: A Special Problem in the Treatment of the Elderly, 638 Adkins PC. See Geelhoed GW

Barnard J. See Greene JW

Dunham WK. The ABCs of Exercise Physiology: A Foundation for Preventive Health Care (CME), 554

Ebersold MJ, Marsh WR, Onofrio BM. Chemonucleolysis in the Treatment of Lumbar Disc Disease (CME), 337

Eden AN. Treatment of Childhood Obesity, 315 Ettinger LD. See Solomon DA

Finlayson RE. Depression That Does Not Respond to Drugs (CME), 504

Fisher JV. The Family Physician's Role in Managing Alcohol and Drug Abuse: A Response to Stephens's Decalogue, 129

Flaker Ġ, Munuswamy K. Evaluation of Syncope With Intracardiac Electrophysiologic Testing (CME), 453

Geelhoed GW. Multiple System Failure in the Critically Injured Patient (CME), 75

Geelhoed GW. The Use and Abuse of Systemic Antibiotics in Surgical Patients (CME), 391

Geelhoed GW, Zimmerman JE, Adkins PC. Uses and Abuses of Albumin: Guidelines for Colloid Therapy, 585 Goldenberg RL, Nelson KG, Humphrey JL, Wayne JB. Mortality and Morbidity in the Perinatal Period, 435

Grau RG. Management of Raynaud's Phenomenon (CME), 200

Grauer K. Differentiating Between Aberrantly Conducted Beats and Ventricular Ectopy (CME), 85

Greene JW, Barnard J. Recurrent Abdominal Pain in Childhood and Adolescence (CME), 256

Holten KB, John PG. Sudden Death in Salicylate Overdose, 191 Humphrey JL. See Goldenberg RL

Jablecki CK. Amyotrophic Lateral Sclerosis (CME), 138 James EJP. See Monzon CM John PG. See Holten KB

Kansal PC. Regulation of Diabetes Mellitus With the Biostator, 490 Katzenstein DA. The Sexual

Transmission of Viral Infections (CME), 18

Kendall AR. Benign Prostatic Hyperplasia: Medical Evaluation, Treatment, and Operative Indications (CME), 680

Kenny JD, Ritter DA. The Intrauterine Growth-Retarded Infant (CME), 689

Laws HL. The Current Role of Surgery in the Management of Duodenal Ulcer (CME), 383

Marsh WR. See Ebersold MJ Mohammad AM. See Monzon CM Monzon CM, Mohammad AM, James EJP. Evaluation of Hemolysis in the Neonate (CME), 211 Munuswamy K. See Flaker G

Nelson KG. See Goldenberg RL

Onofrio BM. See Ebersold MJ Orr JW Jr. The Laser in Gynecology (CME), 567

Panush RS. All Aches Are Not Arthritis: Nonarticular Rheumatism, 375

Pepine CJ. Clinical Use of Calcium-Channel Blockers in Cardiovascular Disease (CME), 13

Petty TL. Chronic Obstructive

Pulmonary Disease Management (CME), 510

Quan MA. See Rodney WM Quinlan RW. A Structured Approach to Antenatal Ultrasound Examinations (CME), 611

Ritter DA. See Kenny JD Rodney WM, Quan MA, Sakiyama R, Vincent C. The Low T<sub>5</sub> (Euthyroid Sick) Syndrome in the Elderly: A Practical Diagnostic Approach (CME), 463

Sakiyama R. See Rodney WM Siegel RL. T and B Cell Abnormalities in Immunologic Diseases (CME), 264

Solomon DA, Ettinger LD. Prophylaxis of Pulmonary Emboli: A Critical Assessment (CME), 330

Stead EA Jr. The Cholesterol Controversy Continues, 249 Susman JL. Problems in Thyroid Endocrinology (CME), 145

Talley JH. A Useful Patient Handout in the Management of Depression, 280

Vincent C. See Rodney WM

Watts C. The Management of Ruptured Intervertebral Disc Disease by Chemonucleolysis, 667 Wayne JB. See Goldenberg RL

Zimmerman JE. See Geelhoed GW

## **Editorial Index**

American Medicine Transformed, 6 Which Physicians Will Care for the Nation's Children? 68 A Decalogue for the Management

A Decalogue for the Management of Alcohol and Drug Abuse, 125 Salicylate Poisoning, 184 The Medical Supermarket:

Futuristic of Decadent? 243 Home Deliveries—Why? 315 Testing, Antiknowledge, and Negat-

ing the Negative, 371
American Medicine and the
Enchanted Machine, 428
The Man With a Renal Cyst. 48

The Medical Supermarket: Futuristic or Decadent? Part II,

Five Aspects of the Healer, 663

### Subject Index

Abdominal pain, recurrent. See Recurrent abdominal pain in childhood and adolescence Aberrantly conducted beats Ashman phenomenon, 89 atrial fibrillation, 95 caveats in diagnosis of, 93 compensatory pauses, 93 explanation of aberrancy, 85 recognition of, 87 regular wide-complex tachydysrhythmias, 97

ventricular ectopy and, 85 Adolescents recurrent abdominal pain, 256

Adult respiratory distress syndrome multiple system failure and, 80 Aerobic exercise

physiologic benefits of, 558 Albumin, human abuses, 586 uses, 585

Amyotrophic lateral sclerosis, 138 Angina

calcium-channel blockers, clinical use of. 13

Antenatal ultrasound examination amniotic fluid volume, 618 evaluating fetus for symmetry of growth, 621

fetal gestational age, 620 fetal position, number, and viability, 612

minimum standards, 611 placental evaluation, 619 screen for fetal developmental anomalies, 625

Antibiotics, systemic prophylactic use, 392 surgical infections, treatment of,

use and abuse in surgical patients, 391

Arrhythmias calcium-channel blockers, clinical use of, 17

Benign prostatic hyperplasia diagnosis, 681 examination of patients with prostatic symptoms, 682 signs and symptoms, 680 treatment, 682 urologic complications of prostatism, 681 Biostator

regulation of diabetes mellitus, 490 Calcium-channel blockers, clinical

use of in cardiovascular disease angina, 13 arrhythmias, 17 Cervical dysplasia

laser therapy, 569 Chemonucleolysis chymopapain, mechanism of action of, 668

chymopapain, pharmacology of, 668

compared with surgery, 670 complications of, 670 indications for, 670 lumbar disc disease, treatment of, 337, 667

results of, 670 Children. See also Intrauterine growth retardation and Infant mortality and morbidity

obesity, treatment of, 321 recurrent abdominal pain, 256 Cholesterol atherosclerosis and, 249 diet and, 250 drugs and serum cholesterol, 250 exercise and, 251, 560

nervous system and, 251 Chronic obstructive pulmonary disease airflow limitation, 511 management, 515

pulmonary rehabilitation, 518 risk factors, 515

Condylomata laser therapy, 577

Deep venous thrombosis pulmonary emboli and, 330 Depression electroconvulsive therapy, 508 management of, 280 refractoriness to drug treatment, 504

Depression management patient handout, 281 Diabetes mellitus Biostator, regulation with, 490 Drugs, use in treatment of elderly,

638 adverse effects, 640 specific drugs, 641

Elderly low T3 (euthyroid sick) syndrome,

use of drugs in treatment of, 638 Electroconvulsive therapy treatment of depression, 508 Euthyroid sick syndrome. See Low T<sub>3</sub> (euthyroid sick) syndrome

Exercise physiology aerobic exercise, physiologic benefits of, 558 basics of, 554 health benefits, 560 maintenance of fluid intake, 559 types of training, 559

Hepatic insufficiency multiple system failure and, 81

Immunologic diseases B-cell abnormalities, 269 T-cell abnormalities, 264 Infant mortality and morbidity, 435 Intrauterine growth retardation definition, 689 developmental follow-up, 698 etiology, 690 growth-retarded infant at birth, 694 management, 696 "Irreversible shock' multiple system failure and, 78

gynecology, use in, 567 Low T<sub>5</sub> (euthyroid sick) syndrome in the elderly, 463 Lumbar disc disease chemonucleolysis, management by, 337, 667 pathophysiology, 667

Multiple system failure, 75 acute renal failure, 79 adult respiratory distress syndrome, 80 CNS failure and death, 81 hepatic insufficiency, 81 "irreversible shock," 78 multiple, progressive, or sequential system failure, 82 organ substitution and the definition of human life, 76 stress ulceration, 80 synergism and organ reserves, 76

Neonate, hemolysis in acquired red-cell disorders, 215 characteristics of red cells in the newborn, 211 congenital red-cell disorders, 216 indications and causes, 214 isoimmunization, 215 Nonarticular rheumatism elbow, 377 fibrositis, 378 foot and ankle, 378 hand and wrist, 377 hip and thigh, 377

childhood, treatment of, 321

Perinatal mortality and morbidity, Premature ventricular contractions. See Ventricular ectopy Pulmonary emboli prophylaxis of, 330

continued on page 710

## Tagamet \* brand of cimetidine

Before prescribing, see complete prescribing informa-tion in SK&F LAB CO. literature or PDR. The following is a brief summary.

a brief summary.

Indications: "Tagamet" (brand of cimetidine) is indicated in the short-term treatment of active duodenal ulcer; in prophylactic use, at reduced dosage, to prevent recurrent duodenal ulcer in patients likely to need surgical treatment, such as those with a history of recurrence or complications and those with concomitant illness in whom surgery would constitute a greater than usual risk (limitation to this population is recommended because the consequences of use beyond one year of continuous Tagamet' therapy are not known); in the short-term treatment of active benign gastric ulcer (there is no information concerning usefulmess of treatment periods of longer than 8 weeks); and in the treatment of pathological hypersecretory disorders (i.e., Zollinger-Ellison syndrome, systemic mastocytosis and multiple endocrine adenomas). In active duodenal ulcer, comitant anlacids should be given as needed for relief of pain; however, simultaneous administration is not recommended.

Contraindications: There are no known contraindications

Precautions: While a weak antiandrogenic effect has been demonstrated in animals. 'Tagamet' has been shown to have no effect on spermatogenesis, sperm count, motility, morphology or *in vitro* fertilizing capacity

In a 24-month toxicity study in rats at dose levels approximately 9 to 56 times the recommended human dose, benign Leydig cell tumors were seen. These were common in both the treated and control groups, and the incidence became significantly higher only in the aged rats receiving "lagamet".

Rare instances of cardiac arrhythmias and hypotension have been reported following the rapid administration of Tagamet' HCI (brand of cimetidine hydrochloride) Injection by intravenous bolus.

Symptomatic response to 'Tagamet' therapy does not preclude the presence of a gastric malignancy. There have been rare reports of transient healing of gastric ulcers despite subsequently documented malignancy.

Reversible confusional states have been reported on occasion, predominantly in severely ill patients.

'Tagamet' has been reported to reduce the hepatic Tagamet has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, chlordiazepoxide, diazepam, lidocaine and theophylline. Clinically significant effects have been reported with the warfarin anticoagulants; therefore, close monitoring of prothrombin time is recommended, and adjustment of the anticoagulant dose may be necessary when Tagamet is administered concomitantly, Interaction with phenytoin, lidocaine and theophylline has also been reported to produce adverse clinical effects.

Lack of experience to date precludes recommending Tagamet for use in pregnant patients, women of child-bearing potential, nursing mothers or children under followers anticipated benefits outweigh potential risks; generally, nursing should not be undertaken in patients taking the drug since cimetidine is secreted in human milk

Decreased white blood cell counts have been reported in Tagamet'-treated patients who also received drugs and/or treatment known to produce neutropenia.

in Tagamet-freated patients who also received drugs and/or treatment known to produce neutropenia. Adverse Reactions: Diarrhea, dizziness, somnolence, headache, rash, mild gynecomastia, Reversible arthratiga, myaligia and exacerbation of joint symptoms in patients with preexisting arthritis have been reported. Reversible confusional states (e.g., mental confusion, agitation, psychosis, depression, anxiety, hallucinations disorientation), predominantly in severely ill patients, have been reported. Reversible impotence in patients with pathological hypersecretory disorders receiving Tagamet, particularly in high dosess between reported reversible impotence in patients with pathological hypersecretory disorders receiving Tagamet, particularly in high dosess been reported. Reversible impotence in patients been reported very rarely. Decreased white blood cell counts in Tagamet-treated patients (approximately 3 per million patients), have been reported, including a few reports of recurrence on rechallenge. These patients generally had serious concomitant illnesses and received drugs and/or treatment known to produce neutropenia. Thrombocytopenia (approximately 3 per million patients) and a few cases of aplastic anemia have also been reported. Increased serum transaminase and creatinine, as well as rare cases of fever, interstitial nephritis and pancreatitis have been reported. Reversible adverse hepatic effects, cholestatic or mixed cholestatic-hepatocellular in nature, have been reported farely. Because of the predominance of cholestatic features, severe parenchymal injury is considered highly unlikely. A single case of biopsy-proven periportal hepatic fibrosis in a patient receiving Tagamet has been reported. How Supplied: Pale Green Tablets: 200 mg. tablets in bottles of 100 and

How Supplied: Pale Green Tablets: 200 mg. tablets in bottles of 100; 300 mg. tablets in bottles of 100 and Single Unit Packages of 100 (intended for institutional use only); 400 mg. tablets in bottles of 60.

Liquid: 300 mg./5 ml., in 8 fl. oz. (237 ml.) amber glass

Injection: 300 mg./2 ml. in single-dose vials and in 8 ml multiple-dose vials, in packages of 10, and in single-dose. prefilled disposable syringes

Date of issuance Apr. 1984

BRS-TG:L50

©SK&F Lab Co., 1984

#### SK&F LAB CO. Carolina, P.R. 00630

## INDEX TO VOLUME 19 continued from page 707

Raynaud's phenomenon calcium-channel blockers, 205 diagnosis and evaluation, 202 pathophysiology, 201 therapy, conventional, 202 vasodilators, experimental, 206 Recurrent abdominal pain in childhood and adolescence definition, 256 familial and psychosocial factors, 259 history, 257 incidence, 256 laboratory examination, 259 management, 262 nonorganic pain, 257 organic causes, 257 physical examination, 259 prognosis, 263 Renal failure, acute multiple system failure and, 79 Ruptured lumbar intervertebral disc disease. See Lumbar disc disease

Salicylate overdose sudden death, 191 treatment of, 192 Stress ulceration multiple system failure and, 80 Sudden death salicylate overdose, 191 Syncope, evaluation with electrophysiologic testing conduction system, 453 sinus node function, 456 syncope caused by arrhythmias,

Thyroid endocrinology dysfunction in the acutely ill, 157 dysfunction in the elderly, 157 physiology, 145 screening, 155 testing, pitfalls of, 152 tests, 149

Ulcer, duodenal surgery, 383 Ultrasound in antenatal examination, 611

Vaginal dysplasia laser therapy, 572 Vagotomy duodenal ulcer and, 384 Ventricular ectopy aberrantly conducted beats and, differentiating between, 85 Viral infections, sexual transmission cytomegalovirus, 22 hepatitis B virus, 23 herpes genitalis, 18 Vulvar dysplasia laser therapy, 572

